GlassScriptPhysician profile
Kimia Menhaji
NPI 1184044182
$5,171.49
in general payments reported to CMS, 2019-2025
30 companies · $1,307 in 2025
The $1,307 reported for 2025 was more than what 75% of Urogynecology and Reconstructive Pelvic Surgery (Obstetrics & Gynecology) providers received nationally (typical 2025 total: $413).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $331 · 2020: $203 · 2021: $790 · 2022: $731 · 2023: $745 · 2024: $1,064 · 2025: $1,307.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,117.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,116.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Coloplast Corp | $993.02 | 2019-2021 | |
| Boston Scientific Corporation | $661.34 | 2022-2025 | Advantage System, Axonics, Bulkamid |
| Axonics, INC. | $487.45 | 2021-2024 | Axonics |
| Sumitomo Pharma America, INC. | $427.95 | 2023-2025 | Gemtesa, Myfembree |
| Abbvie INC. | $379.51 | 2021-2025 | |
| Bluewind Medical | $353.95 | 2024-2025 | Revi |
| Astellas Pharma US INC | $348.30 | 2023-2025 | Veozah |
| Intuitive Surgical, INC. | $313.08 | 2023-2024 | Da Vinci Surgical System |
| Biogen, INC. | $190.73 | 2024-2025 | Zurzuvae |
| Daiichi Sankyo INC. | $127.58 | 2021-2025 | Injectafer |
| Mayne Pharma Commercial LLC | $117.20 | 2021-2025 | |
| Hologic Sales and Service, LLC | $99.71 | 2022-2025 | Aptima, Fetal Fibronectin Enzyme Immunoassay, Thinprep 2000 Processor |
| Evofem Biosciences, INC. | $88.83 | 2024-2025 | Phexxi, Solosec, Phexx |
| Myovant Sciences INC. | $71.84 | 2021-2022 | |
| Pfizer INC. | $68.25 | 2023-2024 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aspira Women'S Health INC | $62.27 | 2022-2024 | Ova1 |
| Coopersurgical, INC. | $51.10 | 2022 | |
| Caldera Medical, INC | $43.66 | 2023 | Desara |
| Bayer Healthcare Pharmaceuticals INC. | $43.43 | 2023-2025 | |
| Baxter Healthcare | $30.17 | 2022 | |
| Organon LLC | $30.14 | 2024 | |
| Medtronic, INC. | $30.05 | 2023-2025 | Nuro |
| Convatec INC. | $24.68 | 2025 | |
| Biotissue Holdings INC. | $23.35 | 2022 | |
| Becton, Dickinson and Company | $22.17 | 2025 | Bd Onclarity |
| Meditrina | $21.10 | 2025 | |
| Pacira Pharmaceuticals Incorporated | $18.16 | 2022 | |
| Mycovia Pharmaceuticals, INC. | $15.58 | 2022 | |
| Avion Pharmaceuticals | $14.52 | 2022 | |
| Therapeuticsmd, INC. | $12.37 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kimia Menhaji listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.